Abstract: This article presents a grid support-based module power balancing strategy for a grid-connected photovoltaic (PV) system fed with a modular cascaded H-bridge inverter. Power imbalance occurs ...

CSL chief financial officer Ken Lim says the global healthcare giant is trying to simplify its organisation after conceding that a slowdown in its ability to make quick decisions had hurt its ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5 billion project. Monday, the Australian biopharma ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Melbourne-based company will ...

C SL has broken ground for an expansion of its state-of-the-art manufacturing facility in Kankakee, Illinois. The newly expanded facility will substantially increase the global biopharma company’s ...

A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan is on track, but the market is still waiting for signs of a strong pulse. The share ...

Feb ⁠18 (Reuters) - ⁠Australia's CSL said on Wednesday it had entered into an exclusive ⁠licensing ⁠agreement with ⁠Eli Lilly and Co, granting it certain ⁠rights to develop ⁠and commercialise ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

Good afternoon, everyone, and thank you for joining us on short notice. My name is Mark Dehring, Head of Investor Relations at CSL. The focus of today's call is CSL's leadership transition, and we ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...